Skip to main content

Table 6 Hypoglycemia Outcomes (ITT population)

From: Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial

  Episodes per patient year Hypoglycemia rates
Hypoglycemia Insulin Glargine mean (95 %CI) NPH insulin mean (95 %CI) Insulin Glargine % (95 %CI) NPH insulin % (95 %CI) p-value*
(N = 327) (N = 323) (N = 327) (N = 323)
Total exposure time in yearsa 144.8 144.5    
Threshold <3.1 mmol/L      
Overall hypoglycemia 0.87 (0.73-1.04) 0.81 (0.67-0.97) 17.7 (13.8-22.3) 15.8 (12.0-20.2) 0.2492
Daytime hypoglycemia 0.59 (0.48-0.73) 0.49 (0.38-0.62) 12.8 (9.4-17.0) 12.1 (8.7-16.1) 0.4751
Nocturnal hypoglycemia 0.28 (0.20-0.38) 0.32 (0.23-0.42) 6.4 (4.0-9.6) 7.4 (4.8-10.9) 0.7150
Threshold <3.9 mmol/L      
Overall hypoglycemia 1.43 (1.24-1.64) 1.46 (1.27-1.67) 25.1 (20.5-30.1) 23.2 (18.7-28.2) 0.2922
Daytime hypoglycemia 1.02 (0.86-1.20) 0.91 (0.76-1.08) 20.5 (16.2-25.3) 18.3 (14.2-22.9) 0.2253
Nocturnal hypoglycemia 0.41 (0.31-0.53) 0.55 (0.44-0.69) 7.6 (5.0-11-1) 10.8 (7.7-14.7) 0.1699
Severe hypoglycemiab 0.00 (NE-0.03) 0.01 (0.00-0.05) 0.0 (0.0-1.1) 0.6 (0.1-2.2) NA
  1. Legend: *McNemar test applied; bone daytime event for each type of insulin; acalculated by adding the exposure time of each patient to each type of insulin